FC2ブログ

バイオの戯言

ライフサイエンスに関する話題についてコメント(戯言?)を述べていくブログです。

【プレスリリースメモ】 RNAi関係 (2013.4.6)  

<Antisense Pharma>
Antisense Pharma participates in Regensburg „NACHT.SCHAFFT.WISSEN.“(2013.4.4)

<Asuragen>
Asuragen launches SuraSeq™ Next Generation Sequencing Services(2013.4.4)

<Bio-Path Holdings>
Bio-Path Holdings Reports Fiscal Year 2012 Operational and Financial Results(2013.4.2)

<Cerulean Pharma>
Cerulean Pharma to Present Data on CRLX101’s HIF-1α Inhibition at the American Association for Cancer Research Annual Meeting(2013.4.4)

<Dicerna Pharmaceuticals>
Dicerna Announces First Patent Grant in Japan to Dicer Substrate siRNA Molecules(2013.4.2)

<EGEN>
EGEN, Inc. Announces a Phase I Clinical Trial for Advanced Ovarian Cancer(2013.3.19)

<Exiqon A/S>
Exiqon A/S - Exiqon A/S – Decisions at annual general meeting 2013(2013.4.4)

<Generex Biotechnology>
Generex Comments on Results of Stockholders` Meeting(2013.4.3)

<Idera Pharmaceuticals>
Idera Announces Clinical Development Progress in Its Autoimmune Diseases Program(2013.4.1)

<Isis Pharmaceuticals>
Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides(2013.4.1)
Isis Initiates Phase 1 Study of ISIS-APOA Rx to Treat Atherosclerosis(2013.4.3)

<Moderna Therapeutics>
AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer(2013.3.21)

<OPKO Health>
OPKO Health Announces Publication of Study Detecting Antibodies in NMO Patients Using OPKO Screening Technology(2013.4.5)

<Regulus Therapeutics>
Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors(2013.4.1)

<Rosetta Genomics>
Rosetta Genomics Announces Acceptance for Publication of Kidney Cancer microRNA Diagnostic Manuscript by Molecular Oncology(2013.4.1)
Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013(2013.4.2)

<Sarepta Therapeutics>
Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy(2013.4.5)

<Valeant Pharmaceuticals>
Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash(2013.4.3)
Valeant Pharmaceuticals Provides Update to Recent Event(2013.4.4)
Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape(2013.4.5)

<アンジェスMG>
・バイオリーダース社との子宮頸部前がん治療ワクチン(CIN 治療ワクチン)のライセンス契約を締結(2013.4.3)
IR情報/IRライブラリー:有価証券報告書等を更新しました(2013.4.4)

<第一三共>
「株式会社 Orphan Disease Treatment Institute」のオフィス開設に関するお知らせ(2013.4.1)


スポンサーサイト
[ 2013/04/06 18:50 ] プレスリリース | TB(0) | CM(0)
コメントの投稿













管理者にだけ表示を許可する
最新ニュース
お気に入り
カレンダー(月別)
07 ≪│2018/08│≫ 09
- - - 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 -
特選品
特許関係の書籍-3
特許関係の書籍-2
特許関係の書籍-1
情報関係の書籍
月別アーカイブ
プロフィール

のぐひで

Author:のぐひで
FC2ブログへようこそ!